Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: Safety and efficacy
Kuter, D.J., Bussel, J.B., Newland, A., Baker, R.I., Lyons, R.M., Wasser, J., Viallard, J-F, Macik, G., Rummel, M., Nie, K. and Jun, S. (2013) Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: Safety and efficacy. British Journal of Haematology, 161 (3). pp. 411-423.
*No subscription required
Romiplostim was effective, safe, and well-tolerated over 6 – 12 months of continuous treatment in Phase 3 trials in patients with immune thrombocytopenia (ITP). This report describes up to 5 years of weekly treatment with romiplostim in 292 adult ITP patients in a long-term, single-arm, open-label study. Outcome measures included adverse events (including bleeding, thrombosis, malignancy, and reticulin/fibrosis), platelet response (platelet count > 50 9 10 9 per litre), and the proportion of patients requiring rescue treatments. Treatment – related serious adverse events were infrequent and did not increase with longer treatment. No new classes of adverse events emerged. Thrombotic events occurred in 6 5% of patients and were not associated with platelet count. Median platelet counts of 50 – 200 9 10 9 per litre were maintained with stable doses of romiplostim (mean 5 – 8 l g/kg; generally self-administered at home) throughout the study. A platelet response was achieved at least once by 95% of patients, with a platelet response maintained by all patients on a median 92% of study visits. There was a low rate of bleeding and infrequent need for rescue treatments. In conclusion, this study demonstrated that romiplostim was safe and well-tolerated over 614 patient-years of exposure in ITP patients, and that efficacy was maintained with stable dosing for up to 5 years of continuous treatment.
|Publication Type:||Journal Article|
|Murdoch Affiliation:||Centre for Haemophilia and Thrombosis Research|
|Publisher:||Blackwell Publishing Inc.|
|Copyright:||© 2013 Blackwell Publishing Ltd|
|Item Control Page|